Drug facts
BrandIngrezza (Valbenazine Tosylate)
No generic valbenazine tosylate has an active Orange Book listing (a generic was first approved 04/05/2024); the latest Ingrezza patent or exclusivity in the Orange Book runs to 08/10/2040. 2 staged generic applications passed FDA review and wait on patents or exclusivity.
Ingrezza was first approved by the FDA on 04/11/2017 under NDA 209241; the application holder is Neurocrine Biosciences Inc.
The latest NADAC for INGREZZA 60 MG CAPSULE is $291.82 per unit (as of 10/28/2026).
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
5,033days until the latest patent expires
- Latest patent
- 08/10/2040Ingrezza Orange Book
- Exclusivity
- 08/18/2030Ingrezza Orange Book
02Competition
- Generics
- No active generic listing in the Orange Book Orange Book
- Staged generics
- 2 passed FDA review, awaiting market entry FDA
- First generic approved
- 04/05/2024 Orange Book
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $291.82 per unitINGREZZA 60 MG CAPSULE, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Neurocrine Biosciences Inc Orange Book
- Application
- NDA 209241 Orange Book
- First approved
- 04/11/2017 Orange Book
- Dosage forms
- capsule
- Routes
- oral
- Other brand names
- Ingrezza Sprinkle
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.